

Trust specifics

Deposit information

Public offering price per unit¹

Minimum investment (\$250 for IRAs)

The Dow Jones Total Market Portfolio, Enhanced Index Strategy 2022-3

Objective

0 12/92

'94

'96

'00

'98

'02

\$10.00

\$1,000,00


The Portfolio seeks above-average capital appreciation. The Portfolio invests in stocks of domestic companies selected by applying separate uniquely specialized enhanced sector strategies." The Portfolio strategy combines ten enhanced sector strategies: the Basic Materials Strategy, the Consumer Goods Strategy, the Consumer Services Strategy, the Energy Strategy, the Financials Strategy, the Health Care Strategy, the Industrials Strategy, e Technology Strategy, the Telecommunications Strategy and the Utilities Strategy. Each strategy makes up at percentage of the initial portfolio as its respective sector makes up of the Dow Jones U.S. Index.

Minimum investment (S	250 for IRAS) ²	\$1,000.00
Deposit date		06/09/22
Termination date		09/08/23
Distribution dates		each October,
		uary and April,
	commencing Oct	
Record dates		each October,
	Jan commencing Oct	uary and April, ober 10, 2022
Term of trust		15 months
Symbol		ITMBBF
Historical 12 month dis	tributions ⁺	\$0.1042
ESTM223 Sales cha	arge and CUSIP	s
Brokerage		
Sales charge ³		
Deferred sales charge		1.35%
Creation and developm	ent fee	0.50%
Total sales charge		1.85%
Last deferred sales cha	rge payment date	03/10/23
CUSIPs		
Cash		46149W-34-4
Reinvest		46149W-35-1
Historical 12 month dis	tribution rate ⁺	1.04%
Fee-based		
Sales charge ³		
Fee-based sales charge		0.50%
CUSIPs		
Fee-based cash		46149W-36-9
Fee-based reinvest		46149W-37-7
Historical 12 month dis	tribution	
rate ⁺ (fee-based)		1.06%

Investors in fee-based accounts will not be assessed the deferred sales charge for eligible fee-based purchases and must purchase units with a fee-based CUSIP

The historical 12 month distributions per unit and each historical 12 month distribution rate of the securities included in the trust are for illustrative purposes only and are not indicative of the trust's actual distributions or distribution rate. The historical 12 month distributions per unit amount is based upon the weighted average of the actual distributions paid by the securities included in the trust over the 12 months preceding the trust's deposit date, and is reduced to account for the officient of foce and expresse which will be incurred when investigation and expenses which will be incurred when investing in a trust. Each historical 12 month distribution rate is calculated by dividing the historical 12 month distributions amount by the trust's initial \$10 public offering price per unit. There is no guarantee the issuers of the securities included in the trust will declare dividends or distributions in the future. Due to declare dividends or distributions in the future. Due to the negative economic impact across many industries caused by the recent COVID-19 outbreak, certain issuers of the securities included in the trust may elect to reduce the amount of, or cancel entirely, dividends and/or distributions paid in the future. As a result, the historical 12 month distributions per unit and each, the historical 12 month distribution rate will likely be higher, and in some cases significantly higher, than the actual distributions rate achieved by the trust. The distributions paid by the trust, as well as the corresponding rates, may be higher or lower than the figures shown due to certain factors that may include, but are not limited to, a change in the dividends or distributions paid by issuers, actual expenses incurred, currency fluctuations, the sale of trust securities to pay any deferred sales charges, trust fees and expenses, variations in the trust's per unit price, or with the call, maturity or the sale of securities in the trust. Distributions made by certain securities in the trust. Distributions made by certain securities in the trust may include non-ordinary income. * An enhanced sector (or "index") strategy refers to a unit investment trust strategy, sponsored by Invesco Capital Markets, Inc., that seeks to outperform an index by investing in an endertively certain custed of steels from

investing in an objectively selected subset of stocks from the same index.



'04

'06

'08

Annual total return	Portfolio Strategy	DJ U.S. Index	S&P 500 Index
1993	18.92%	9.78%	10.06%
1994	-1.65	0.21	1.32
1995	34.72	36.62	37.58
1996	24.82	22.02	22.96
1997	36.07	31.81	33.36
1998	18.58	24.90	28.58
1999	64.94	22.72	21.04
2000	21.60	-9.23	-9.10
2001	21.80	-11.95	-11.89
2002	-6.12	-22.08	-22.10
2003	52.55	30.75	28.68
2004	19.06	12.01	10.88
2005	14.07	6.33	4.91
2006	10.44	15.63	15.79
2007	-2.97	6.14	5.49
2008	-46.84	-37.15	-37.00
2009	54.41	28.82	26.47
2010	20.85	16.72	15.06
2011	-3.45	1.38	2.11
2012	10.21	16.56	16.00
2013	41.20	32.96	32.38
2014	11.05	12.94	13.68
2015	-4.39	0.62	1.37
2016	17.40	12.24	11.95
2017	17.87	21.48	21.82
2018	-14.72	-4.98	-4.39
2019	25.87	31.14	31.48
2020	5.26	20.39	18.39
2021	23.49	26.47	28.68
Thru 05/31/22	-13.28	-13.97	-12.76

Average annual

total return (for the period ended on 12/31/21)	Portfolio Strategy	DJ U.S. Index	S&P 500 Index
1-Year	23.49%	26.47%	28.68%
3-Year	17.84	25.92	26.05
5-Year	10.46	18.18	18.46
10-Year	12.30	16.37	16.54
15-Year	7.51	10.76	10.65
20-Year	9.70	9.81	9.52
25-Year	13.76	9.86	9.75
Inception (01/01/93)	14.39	10.74	10.75
1993 - 2021	Portfolio Strategy	DJ U.S. Index	S&P 500 Index
Standard deviation	22.35%	17.51%	17.52%
Sharpe ratio	0.55	0.49	0.49
Source: Bloomberg L.P.			

The graph represents a hypothetical \$10,000 investment in the trust strategy (not any actual trust) and the Dow Jones U.S. Index and the S&P 500 Index from 12/31/92 through 05/31/22. The graph assumes the sum of the initial investment (\$10,000) and all dividends (including those on stocks trading ex-dividend as of the last day of the year) and appreciation during a year are reinvested at the end of that year.

'12

'14

'16

'18

05/22

'10

All strategy performance is hypothetical (not any actual trust) and reflects trust sales charges at the beginning of each calendar year of 1.85% and expenses but not brokerage commissions on stocks or taxes. Past performance is no guarantee of future results. Actual returns will vary from hypothetical strategy returns due to timing differences, expenses and because the trust may not be invested equally in all stocks or be fully invested at all times. In any given year the strategy may lose money or underperform the index. Returns are calculated by taking year-end prices, subtracting them from the prices at the end of the following year (adjusting for any stock splits that might have occurred during the year) and adding dividends received for the period divided by starting price. Average annual total return and total return measure change in the value of an investment plus dividends, assuming quarterly reinvestment of dividends. Average annual total return reflects annualized change while total return reflects aggregate change and is not annualized.

Standard deviation is a measure of volatility that represents the degree to which an investment's performance has varied from its average performance over a particular period. Standard deviation does not compare the volatility of an investment relative to other investments or the overall stock market. The more an investment's return varies from the investment's average return, the more volatile the investment. Standard deviation is based on past performance and is no guarantee of future results.

The Sharpe ratio is a risk-adjusted measure calculated using standard deviation on excess return to determine reward per unit of risk. The higher the Sharpe ratio, the better the historical risk-adjusted performance.

Please keep in mind that high, double-digit and/or triple-digit returns are highly unusual and cannot be sustained. Investors should also be aware that these returns were primarily achieved during favorable market conditions.

See page 4 for the footnotes on trust specifics.

Not a Deposit Not FDIC Insured Not Guaranteed by the Bank May Lose Value Not Insured by any Federal Government Agency

Portfolio composition (As of the business day before deposit date)

Portfolio composition (As of the busine	ss day before
Basic Materials	
Alcoa Corporation	AA
Celanese Corporation	CE
CF Industries Holdings, Inc.	CF
Cleveland-Cliffs, Inc.	CLF
Dow, Inc.	DOW
DuPont de Nemours, Inc. Eastman Chemical Company	DD EMN
Huntsman Corporation	HUN
Ingevity Corporation	NGVT
International Flavors & Fragrances, Inc.	IFF
LyondellBasell Industries N.V.	LYB
Mosaic Company	MOS
Newmont Corporation	NEM
Nucor Corporation	NUE
Olin Corporation	OLN
Reliance Steel & Aluminum Company	RS
Scotts Miracle-Gro Company - CL A	SMG STLD
Steel Dynamics, Inc. United States Steel Corporation	X
Westlake Corporation	WLK
Consumer Goods	
Archer-Daniels-Midland Company	ADM
BorgWarner, Inc.	BWA
Capri Holdings, Ltd.	CPRI
D.R. Horton, Inc.	DHI
Ford Motor Company	F
Lamb Weston Holdings, Inc.	LW
Levi Strauss & Company - CL A	LEVI
Molson Coors Beverage Company - CL B	TAP
NVR, Inc.	NVR
Performance Food Group Company	PFGC
Pilgrim's Pride Corporation	PPC
PulteGroup, Inc. PVH Corporation	PHM PVH
Ralph Lauren Corporation - CL A	RL
Tapestry, Inc.	TPR
Thor Industries, Inc.	THO
Toll Brothers, Inc.	TOL
Tyson Foods, Inc CL A	TSN
US Foods Holding Corporation	USFD
V.F. Corporation	VFC
Consumer Services	
Albertsons Companies, Inc CL A	ACI
Altice USA, Inc CL A	ATUS
AMERCO	UHAL
AutoNation, Inc.	AN
Charter Communications, Inc CL A	CHTR CHGG
Chegg, Inc. Comcast Corporation - CL A	CMCSA
Cracker Barrel Old Country Store, Inc.	CBRL
Grand Canyon Education, Inc.	LOPE
Kroger Company	KR
Liberty SiriusXM Group	LSXMK
Lithia Motors, Inc.	LAD
Nexstar Media Group, Inc CL A	NXST
Planet Fitness, Inc CL A	PLNT
Southwest Airlines Company	LUV
Sprouts Farmers Market, Inc.	SFM
TJX Companies, Inc.	TJX
Ulta Beauty, Inc. Walt Disney Company	ULTA DIS
Warner Bros. Discovery, Inc Series A	WBD
	1100
Energy APA Corporation	APA
Chevron Corporation	CVX
ConocoPhillips	COP
Continental Resources, Inc.	CLR
Coterra Energy, Inc.	CTRA

deposit date)	
Devon Energy Corporation	DVN
Diamondback Energy, Inc.	FANG
EOG Resources, Inc.	EOG
Exxon Mobil Corporation	XOM
First Solar, Inc.	FSLR
HF Sinclair Corporation Marathon Oil Corporation	DINO MRO
Marathon Petroleum Corporation	MPC
Occidental Petroleum Corporation	OXY
ONEOK, Inc.	OKE
Ovintiv, Inc.	OVV
Phillips 66	PSX
Pioneer Natural Resources Company	PXD
Targa Resources Corporation	TRGP
Valero Energy Corporation	VLO
Financials	
Ally Financial, Inc.	ALLY
Brighthouse Financial, Inc.	BHF
Capital One Financial Corporation	COF
Citizens Financial Group, Inc. Discover Financial Services	CFG
Essent Group, Ltd.	DFS ESNT
Everest Re Group, Ltd.	RE
Fidelity National Financial, Inc.	FNF
First American Financial Corporation	FAF
Jackson Financial Incorporation - CL A	JXN
Janus Henderson Group plc	JHG
Jefferies Financial Group, Inc.	JEF
Lincoln National Corporation	LNC
Old Republic International Corporation	ORI
OneMain Holdings, Inc.	OMF
Prosperity Bancshares, Inc.	PB
State Street Corporation Synchrony Financial	STT SYF
	TFC
Truist Financial Corporation	
Unum Group	UNM
Unum Group Health Care	UNM
Unum Group Health Care AbbVie, Inc.	UNM
Unum Group Health Care AbbVie, Inc. Amgen, Inc.	UNM ABBV AMGN
Unum Group Health Care AbbVie, Inc.	UNM
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company	UNM ABBV AMGN BMY
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG	UNM ABBV AMGN BMY CRSP
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI MRK MRNA
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI MRK MRNA OGN
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI MRK MRNA OGN PFE
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI MRK MRNA OGN
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI MRVI MRNA OGN PFE QDEL
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI MRVI MRVA OGN PFE QDEL REGN
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI MRVI MRVI MRNA OGN PFE QDEL REGN THC
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI MRVI MRVI MRVA OGN PFE QDEL REGN THC UTHR
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI MRVI MRVI MRVA OGN PFE QDEL REGN THC UTHR VTRS
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Vir Biotechnology, Inc. Industrials Allison Transmission Holdings, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI MRVI MRVI MRVA OGN PFE QDEL REGN THC UTHR VTRS VIR ALSN
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Vir Biotechnology, Inc. Applied Industrial Technologies, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRVI MRVI MRVI MRVI MRVI MRVI MRVI
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Vir Biotechnology, Inc. Industrials Allison Transmission Holdings, Inc. Avnet, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRK MRNA OGN PFE QDEL REGN THC UTHR VTRS VIR VIR ALSN ALSN
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Vir Biotechnology, Inc. Applied Industrial Technologies, Inc. Avnet, Inc. Builders FirstSource, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRK MRNA OGN PFE QDEL REGN THC UTHR VTRS VIR ALSN ALSN ALSN ALSN
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Vir Biotechnology, Inc. Industrials Allison Transmission Holdings, Inc. Avnet, Inc. Builders FirstSource, Inc. Carlisle Companies, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRK MRNA OGN PFE QDEL REGN THC UTHR VTRS VIR ALSN ALSN ALSN ALSN CSL
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Vir Biotechnology, Inc. Industrials Allison Transmission Holdings, Inc. Avnet, Inc. Builders FirstSource, Inc. Carlisle Companies, Inc. Concentrix Corporation	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRK MRNA OGN PFE QDEL REGN THC UTHR VTRS VIR ALSN ALSN ALSN ALSN CNXC
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Vir Biotechnology, Inc. Industrials Allison Transmission Holdings, Inc. Avnet, Inc. Builders FirstSource, Inc. Carlisle Companies, Inc. Concentrix Corporation Fleetcor Technologies, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRK MRNA OGN PFE QDEL REGN THC UTHR VTRS VIR ALSN ALSN ALSN ALSN CSL
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Vir Biotechnology, Inc. Industrials Allison Transmission Holdings, Inc. Avnet, Inc. Builders FirstSource, Inc. Carlisle Companies, Inc. Concentrix Corporation	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRK MRNA OGN PFE QDEL REGN THC UTHR VTRS VIR VIR ALSN ALSN ALSN ALSN ALSN CNXC CNXC
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Vir Biotechnology, Inc. Industrials Allison Transmission Holdings, Inc. Axnet, Inc. Builders FirstSource, Inc. Carlisle Companies, Inc. International Paper Company	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRK MRNA OGN PFE QDEL REGN THC UTHR VTRS VIR VIR VIR ALSN AIT AVT BLDR CSL CNXC FLT
Unum Group Health Care AbbVie, Inc. Amgen, Inc. Bristol-Myers Squibb Company CRISPR Therapeutics AG DaVita Inc. Exelixis, Inc. Gilead Sciences, Inc. Hologic, Inc. Horizon Therapeutics plc Maravai LifeSciences Holdings, Inc CL A Merck & Company, Inc. Moderna, Inc. Organon & Company Pfizer, Inc. QuidelOrtho Corporation Regeneron Pharmaceuticals, Inc. Tenet Healthcare Corporation United Therapeutics Corporation Viatris, Inc. Vir Biotechnology, Inc. Anplied Industrial Technologies, Inc. Applied Industrial Technologies, Inc. Concentrix Corporation Fleetcor Technologies, Inc. International Paper Company Jabil, Inc.	UNM ABBV AMGN BMY CRSP DVA EXEL GILD HOLX HZNP MRVI MRK MRNA OGN PFE QDEL REGN THC UTHR VTRS VIR VIR VIR ALSN AIT AVT BLDR CSL CNXC FLT

Littelfuse, Inc.	LFUS
Louisiana-Pacific Corporation	LPX
ManpowerGroup, Inc.	MAN
Owens Corning	00
PerkinElmer, Inc.	PK
Univar Solutions, Inc.	UNVR
WestRock Company	WRK
WEX, Inc.	WEX
XPO Logistics, Inc.	XPO
Technology	
ACI Worldwide, Inc.	ACIW
Amdocs, Ltd.	DOX
Aspen Technology, Inc.	AZPN
Cirrus Logic, Inc.	CRUS
Cognizant Technology Solutions Corporation - CL A	CTSH
DXC Technology Company	DXC
eBay, Inc.	EBAY
Hewlett Packard Enterprise Company	HPE
Intel Corporation	INTC
Liberty Global plc - CL C	LBTYK
Lumentum Holdings, Inc.	LITE
Meta Platforms, Inc.	META
Micron Technology, Inc.	MU
MKS Instruments, Inc.	MKS
Qorvo, Inc.	QRVC
Skyworks Solutions, Inc.	SWKS
TD SYNNEX Corporation	SNX
Universal Display Corporation	OLED
Xerox Holdings Corporation	XRX
Ziff Davis, Inc.	ZD
Telecommunications	
AT&T, Inc.	Т
Frontier Communications Parent, Inc.	FYBR
T-Mobile US, Inc.	TMUS
United States Cellular Corporation	USM
Verizon Communications, Inc.	VZ
Utilities	
AES Corporation	AES
ALLETE, Inc.	ALE
American Water Works Company, Inc.	AWK
Atmos Energy Corporation	ATC
Avista Corporation	AVA
Black Hills Corporation	BKH
Edison International	EIX
Essential Utilities, Inc.	WTRG
Evergy, Inc.	EVRG
Exelon Corporation	EXC
FirstEnergy Corporation	FE
Hawaiian Electric Industries, Inc.	HE
National Fuel Gas Company	NFG
NorthWestern Corporation	NWE
,	NRG
NRG Energy, Inc.	PCG
NRG Energy, Inc. PG&E Corporation	-
NRG Energy, Inc. PG&E Corporation Pinnacle West Capital Corporation	
NRG Energy, Inc. PG&E Corporation Pinnacle West Capital Corporation Portland General Electric Company	POR
NRG Energy, Inc. PG&E Corporation Pinnacle West Capital Corporation	PNW POR PPL UGI

The trust portfolio is provided for informational purposes only and should not be deemed as a recommendation to buy or sell the individual securities shown above. Invesco's history of offering unit investment trusts began with the acquisition of the Sponsor by Invesco Ltd. in June 2010. Invesco unit investment trusts are distributed by the Sponsor, Invesco Capital Markets, Inc. and broker dealers including Invesco Distributors, Inc. Both firms are indirect, wholly owned subsidiaries of Invesco Ltd.



of the initial date of deposit. For a complete description of these characteristics refer to the following page.

The Dow Jones Total Market Portfolio, Enhanced Index Strategy:

The Dow Jones Total Market Portfolio, Enhanced Index Strategy combines all of the enhanced sector strategies listed below into one comprehensive investment that spans all the sectors within the Dow Jones U.S. Index.

Basic Materials Strategy	20 stocks	Industrials Strategy	20 stocks
Consumer Goods Strategy	20 stocks	Technology Strategy	20 stocks
Consumer Services Strategy	20 stocks	Telecommunications Strategy	5 stocks
Energy Strategy	20 stocks	Utilities Strategy	20 stocks
Financials Strategy	20 stocks	The Dow Jones Total Market Portfolio,	
Health Care Strategy	20 stocks	Enhanced Index Strategy*	185 stocks

*Although each enhanced sector strategy is designed to produce a certain number of stocks, it is possible that a particular strategy could produce less. For example, certain series of this strategy have resulted in less than 10 stocks within the Telecommunications Strategy, as shown in the chart above. Beginning with the stocks in the Dow Jones U.S. Index, the strategies exclude the bottom 1% of stocks based on market capitalization. The strategies then rank each remaining company in the Dow Jones U.S. respective sector index from highest to lowest based on the following strategy screens for each: Basic materials strategy-Dividend yield, Price/book value ratio, Price/free cash flow ratio, Price/sales ratio, Price/sales to five-year average, Operating margin. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Basic Materials Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Price/Book Value Ratio is ranked higher. This trust invests in the basic materials sector. Basic materials companies are subject to price and supply fluctuations, excess capacity, economic recession, domestic and international politics, government regulations, volatile interest rates, consumer spending trends and overall capital spending levels. Consumer goods strategy—Price/cash flow ratio, Operating income change last quarter, Total return for the past six months, One-year earnings growth, Long-term expected profit growth, Dividend yield to five-year median, The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Consumer Goods Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score the stock with the bipter score for Long-Term Expected Brotter Rowth is ranked bipter. This trust investing in the score with the stock of Companies that manufacture score, the stock with the higher score for Long-Term Expected Profit Growth is ranked higher. This trust invests in the consumer goods sector. Companies that manufacture distribute and provide consumer products face risks such as intense competition, the lack of serious barriers to entry for on-line entrants, economic recession and a slowdown in consumer spending trends. A portfolio concentrated in a single market sector may present more risk than a portfolio broadly diversified over several sectors. Consumer services strategy–Price/earnings ratio, Price/sales to five-year average, Total return for the past six months, EPS change last quarter, Long-term expected profit growth, Cash flow to net income. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Consumer Services Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Long-Term Expected Profit Growth is ranked higher. This trust invests in the consumer services sector. Companies that provide consumer services

With the higher score for Long-term Expected Profit Growth is ranked higher. This trust invests in the consumer services sector. Companies that provide consumer services face risks such as intense competition, the lack of serious barriers to entry for on-line entrants, economic recession and a slowdown in consumer spending trends. A portfolio concentrated in a single market sector may present more risk than a portfolio broadly diversified over several sectors. **Energy strategy**—Enterprise value to EBITDA, Price/sales ratio, Price/sales to three-year average, Five-year earnings growth, Long-term expected profit growth, Gross margin trend. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Oil & Gas Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Long-Term Expected Profit forwth is ranked higher. This trategy industry. There are certain risks specific to the energy score for Long-Term industry. Expected Profit Growth is ranked higher. This trust invests in the energy industry. There are certain risks specific to the energy sector, including the potential adverse effect of state and federal regulation and increasing costs of natural resources.

Financials strategy-Price/earnings ratio, Price/book value ratio, Price/sales ratio, Earnings predictability, Long-term expected profit growth, Tangible book one-year change. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Financials Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Tangible Book One-Year Change is ranked higher. The trust invests in the financial services industry and may present more risk than a more diversified investment. There are certain risks Health care strategy-Enterprise value to EBITDA, Price/earnings ratio, Price/free cash flow ratio, One-year net income growth, Return on equity, Gross margin. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow

Jones U.S. Health Care Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Return on Equity is ranked higher. This trust invests in the health care sector. There are certain risks specific to the health care companies such as governmental regulation and the risk that a product may never come to pass.

Industrials strategy—Price/earnings ratio, Price/free cash flow ratio, Long-term expected profit growth, EPS revisions current quarter, EPS surprise last quarter, Total return for the past six months. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Industrials Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Price/Earnings Ratio is ranked higher. This trust invests in the industrials sector. General risks of industrials companies include the general state of the economy, intense competition, consolidation, domestic and international politics, excess capacity and consumer spending trends.

Technology strategy-Price/book value ratio, Price/sales to five-year average, Price/sales ratio, Total return for the past six months, Net profit margin, Tangible book five-year change. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Technology Index. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Total Return for the Past Six Months is ranked higher. This trust invests in the technology industry. There are certain risks specific to information technology stocks such as volatile stock prices, rapid product obsolescence, and speculative trading.

Telecommunications strategy–Dividend yield, Enterprise value to EBITDA, Price/cash flow ratio, Three-year sales growth, Total return for the past six months, Asset turnover trend. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Telecommunications Index. The strategy then ranks the remaining stocks by total score and selects the top 10 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Enterprise Value to EBITDA is ranked higher. This trust invests in the telecommunications industry. There are certain risks specific to telecommunication stocks such as volatile stock prices, rapid product obsolescence, and speculative trading as well as government changes in regulations.

Utilities Strategy-Price/earnings ratio, Price/book value ratio versus three-year average, Price/sales to three-year average, Price/cash flow ratio, Long-term expected profit growth, EBIT margin. The strategy assigns each stock a rank score for each of these categories with the lowest score being 1 and the highest score being the total number of stocks in the Dow Jones U.S. Utilities lindex. The strategy then ranks the remaining stocks by total score and selects the top 20 stocks, provided that the stock of any Invesco affiliate will be removed and replaced with the stock with the next highest ranking. If two stocks are assigned the same total score, the stock with the higher score for Price/ Earnings Ratio is ranked higher. This trust invests in the utility industry, it may be highly susceptible to any economic, political, or regulatory occurrences affecting this industry.

In addition, for all strategies listed above, a company will be excluded and its stock will be replaced with the stock with the next highest total score, if the company is an affiliate of the Sponsor, if there is any restriction on the Sponsor's ability to purchase a company's stock, or, if based on publicly available information as of the selection date, a proposed corporate action would result in it not being the surviving company following a business combination or in its security being delisted.

Asset turnover trend—The median asset turnover for the four most recent quarters divided by the median asset turnover of the 12 most recent quarters. Asset turnover is the sum of the four most recent quarters of sales divided by the average of the four most recent quarters of assets. Cash flow to net income—Sum of the four most recent quarters of cash flow divided by sum of the four most recent quarters of net income. Cash flow is defined as income before extraordinary items plus depreciation and amortization. Dividend yield-The indicated annual dividend divided by the current stock price. Dividend yield to five-year median-Current dividend yield divided by the median dividend yield over the past 60 months. Earnings predictability-A ratio that seeks to measure of the stability of year-to-year earnings growth over the past 20 quarters. Calculated by dividing the standard deviation of year-to-year changes in per-share earnings by the average year-to-year change in per-share earnings. EBIT margin—Earnings before interest and taxes (EBIT) divided by sales. Enterprise value to EBITDA—Enterprise value divided by earnings before interest, taxes, depreciation and amortization (EBITDA). Enterprise value equials stock market capitalization plus sum of debt and preferred stock minus cash and cash equivalents. EPS change last quarter-Year-to-year change in operating earnings per share (EPS). Operating earnings exclude the effect of all nonrecurring items, including cumulative effect of accounting changes, discontinued operations, extraordinary items, special items, and one-time income tax expenses/benefits. EPS revisions current quarter-The net percentage of positive profit-estimate revisions. First, the number of earnings estimates for the next fiscal quarter that have been decreased from the prior month are subtracted from the number that have been increased. Next, that result is divided by the total number of earnings estimates for the guarter. EPS surprise last guarter-The difference between last quarter's actual earnings per share and the average estimate, divided by the absolute value of the actual earnings per share. Five-year earnings growth-Current price/sales ratio divided by median price/sales ratio over the past 60 months. Gross margin-Net sales in most recent four guarters minus cost of goods sold in most recent four quarters, with this total then divided by net sales. Gross margin trend-The median gross margin over the past four quarters divided by the median gross margin over the past 12 quarters. Long-term expected profit growth—The simple average of analysts' estimates for five-year growth in earnings per share. Net profit margin—Net income divided by sales. One-year earnings growth—The difference between operating earnings per share in the most recent four quarters share. Net profit margin–Net income divided by sales. One-year earnings growth–The difference between operating earnings per share in the most recent four quarters one year earlier, expressed as a percentage. Operating income change last quarter–The difference between operating income in the latest quarter and the year-earlier quarter. Operating margin–Operating income before depreciation divided by sales, calculated for most recent four quarters one year earlier, expressed as a percentage. Operating income change last quarter–The difference between operating income before depreciation divided by sales, calculated for most recent four quarters. One-year net income growth–The difference between net earnings per share in the most recent four quarters and net earnings per share in the discontinued operations and extraordinary items. Price/book value ratio–Stock price divided by current book value per share. Price/book value ratio versus three-year average–The current price/book value ratio divided by the median of the price/book value ratio over the past 36 months. Price/cash flow ratio–Stock price divided by per-share cash flow over past four quarters. Price/free cash flow ratio–Stock price divided by earnings per share from operations over past four quarters. Price/free cash flow ratio–Stock price divided by mersents the net change in cash from all items classified in the operating activities section on a statement of cash flow, minus capital spending and cash dividends. Price/sales ratio–Stock price divided by median price/sales ratio over the past 36 months. Price/sales to five-year average–Current price/sales ratio divided by median price/sales ratio over the past 36 months. Price/sales to five-year average–Current price/sales ratio over past 60 months. Return on equity–Income before extraordinary items over most recent four quarters divided by average for common equity over four most recent quarters. Tangible book one-year change–The change in tangible shareholders equity per share over the most recent four share over the past five years. Tangible shareholders equity equals shareholders equity minus intangible assets, such as goodwill. Three-year sales growth–The difference between per share sales in the most recent four quarters and per-share sales in the four quarters three years earlier, expressed as a percentage. Total return for the past six months-The percentage return on a stock over most recent six months, reflecting dividends and change in stock price.

About risk

There is no assurance the trust will achieve its investment objective. An investment in this unit investment trust is subject to market risk, which is the possibility that the market values of securities owned by the trust will decline and that the value of trust units may therefore be less than what you paid for them. Recently, an outbreak of a respiratory disease caused by a novel coronavirus, COVID-19, has spread globally in a short period of time, resulting in the disruption of, and delays in, production and supply chains and the delivery of healthcare services and processes, as well as the cancellation of organized events and educational institutions, quarantines, a decline in consumer demand for certain goods and services, and general concern and uncertainty. COVID-19 and its effects have contributed to increased volatility in global markets, severe losses, liquidity constraints, and lowered yields. The duration of such effects cannot yet be determined but could be present for an extended period of time and may adversely affect the value of your Units. This trust is unmanaged and its portfolio is not intended to change during the trust's life except in limited circumstances. Accordingly, you can lose money investing in this trust. The trust should be considered as a part of a long-term investment strategy and you should consider your ability to pursue it by investing in successive trusts, if available. You will realize tax consequences associated with investing from one series to the next.

Common stocks do not assure dividend payments. Dividends are paid only when declared by an issuer's board of directors and the amount of any dividend may vary over time. There can be no guarantee or assurance that companies will declare dividends in the future or that if declared, they will remain at current levels or increase over time. The financial condition of an issuer may worsen or its credit ratings may drop, resulting in a reduction in the value of your Units. This may occur at any point in time, including during the initial offering period.

You could experience dilution of your investment if the size of the Portfolio is increased as Units are sold. There is no assurance that your investment will maintain its proportionate share in the Portfolio's profits and losses. Stocks of smaller capitalization companies are often more volatile than those of larger companies as a result of several factors such as limited trading volumes,

products or financial resources, management inexperience and less publicly available information.

The Portfolio is concentrated in securities issued by companies in the technology industry. The technology industry faces risks related to rapidly changing technology, rapid product obsolescence, cyclical market patterns, evolving industry standards and frequent new product introductions. Negative developments in this industry will affect the value of your investment more than would be the case for a more diversified investment.

Value, blend and growth are types of investment styles. Growth investing generally seeks stocks that offer the potential for greater-than-average earnings growth, and may entail greater risk than value or blend investing. Value investing generally seeks stocks that may be sound investments but are temporarily out of favor in the marketplace, and may entail less risk than growth investing. A blend investment combines the two styles. The Dow Jones U.S. Index measures the performance of the U.S. equity broad market. The index is comprised of all the companies in the Dow Jones Large-Cap

Index, Dow Jones Mid-Cap Index and Dow Jones Small-Cap Index.

Dow Jones Mid-Cap Index and Dow Jones Small-Cap Index. Dow Jones U.S. Index is a product of S&P Dow Jones Indices, a licensed trademark of CME Group Index Services LLC (CME), and has been licensed for use for certain purposes by Invesco and the trust. The Portfolio, based on the Dow Jones U.S. Index, the Dow Jones U.S. Basic Material Index, the Dow Jones U.S. Consumer Goods Index, the Dow Jones U.S. Consumer Services Index, the Dow Jones Oil & Gas Index, the Dow Jones Financials Index, the Dow Jones Health Care Index, the Dow Jones Industrials Index, the Dow Jones Technology Index, the Dow Jones Telecommunications Index and the Dow Jones Utilities Index, is not sponsored, endorsed, sold or promoted by Dow Jones, CME, or their respective affiliates, and Dow Jones, CME and their respective affiliates make no representation regarding the advisability of investing in this product.

The Standard & Poor's 500 Index is an unmanaged index generally representative of the U.S. stock market.

Indices are statistical composites and their returns do not include payment of any sales charges or fees an investor would pay to purchase the securities they represent. Such costs would lower performance. It is not possible to invest directly in an index. The historical performance of the indices are shown for illustrative purposes only; it is not meant to forecast, imply or guarantee the future performance of any particular investment or the trust, which will vary. 1 Including sales charges. As of deposit date.

Represents the value of 100 units on the deposit date. The value of the minimum investment amount of 100 units may be greater or less than \$1,000.00 following the deposit date.

3 Assuming a public offering price of \$10 per unit. There is no initial sales charge if the public offering price per unit is \$10 or less. If the public offering price per unit exceeds \$10, an initial sales charge is paid at the time of purchase. The per unit amount of the initial sales charge is 1.85% of the dollar amount that the public offering price per unit exceeds \$10.

Before investing, investors should carefully read the prospectus and consider the investment objectives, risks, charges and expenses. For this and more complete information about the trust, investors should ask their advisor(s) for a prospectus or download one at invesco.com/uit.

This does not constitute a recommendation of any investment strategy or product for a particular investor. Investors should consult a financial professional before making any investment decisions.

The Dow Jones Total Market Portfolio, Enhanced Index Strategy 2022-3